A brain-only CAR-T therapy from UCSF wiped out a deadly childhood brain cancer in every mouse tested; human trials could start in April 2027
The therapy targets diffuse midline glioma, a tumour that kills nearly all children within a year of diagnosis.

- Cancer: diffuse midline glioma (DMG)
- Published in Science Translational Medicine
- Human trials possibly from April 2027
The breakthrough
Scientists at the University of California, San Francisco engineered immune cells, called B-SYNC CAR-T, that switch on only inside the brain. Delivered directly into the brain, they eliminated diffuse midline glioma in every mouse tested across two models, while standard CAR-T cells could not control the tumours. The results are in Science Translational Medicine.
Seven weeks later, every treated mouse rejected a fresh dose of tumour cells, and the cells were still working more than 70 days on.
What's next
UCSF is preparing a first human trial, possibly from April 2027, co-led by Dr Sabine Mueller. It has not yet been tested in people, but for a cancer with almost no treatment options, it is real hope.






